Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/ijms18091904
Keywords
acute lymphoblastic leukemia; oncogenes; PI3K; AKT; targeted therapy
Funding
- Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)
- Progetto di Ricerca di Ateneo (PRAT)
- Progetto di Ricerca di Ateneo (Universita di Padova)
- Progetto di Ricerca di Ateneo (CDA) [152403]
- Istituto Oncologico Veneto fund (Progetto Sinergia tra Oncologia Molecolare e Clinica) [5 X 1000]
Ask authors/readers for more resources
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease caused by the malignant transformation of immature progenitors primed towards T-cell development. Clinically, T-ALL patients present with diffuse infiltration of the bone marrow by immature T-cell blasts high blood cell counts, mediastinal involvement, and diffusion to the central nervous system. In the past decade, the genomic landscape of T-ALL has been the target of intense research. The identification of specific genomic alterations has contributed to identify strong oncogenic drivers and signaling pathways regulating leukemia growth. Notwithstanding, T-ALL patients are still treated with high-dose multiagent chemotherapy, potentially exposing these patients to considerable acute and long-term side effects. This review summarizes recent advances in our understanding of the signaling pathways relevant for the pathogenesis of T-ALL and the opportunities offered for targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available